A Study of DS3610a in Participants With Advanced Solid Tumor
This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.
| Condition(s) | Solid Tumors, Metastatic Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors. |
| Who can participate | Key Inclusion Criteria: * Sign and date the main ICF, prior to the start of any trial-specific procedures. * Adults ≥18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old). * Relapsed from, refractory to, or intolerant to appropriate therapies (eg, SoC) to provide clinical benefit for their condition as assessed by their physician and/or investigator. * Is willing and able to provide an adequate pretreatment tissue sample prior to trial intervention or archival tumor tissue sample. * Has measurable disease based on local CT/MRI imaging as assessed by the investigator per RECIST v1.1; radiographic tumor assessment must be performed within 28 days prior to initiation of trial interventi |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Daiichi Sankyo |
| Locations | Chūōku, Japan; Kashiwa, Japan |
| Start date | 2025-10-09 |
| NCT ID | NCT07159126 |
| Official listing | https://clinicaltrials.gov/study/NCT07159126 |